RHYTHM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.68 USD | -2.73% |
|
-2.94% | -22.38% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,009 | 1,314 | 501.7 | 1,641 | 2,717 | 2,176 | - | - |
| Enterprise Value (EV) 1 | 715.7 | 1,141 | 206.8 | 1,308 | 2,441 | 1,914 | 1,951 | 1,897 |
| P/E ratio | -5.95 x | -9.78 x | -7.13 x | -8.39 x | -14.4 x | -8.04 x | -14.7 x | 1,647 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 159 x | 69.4 x | 35.1 x | 17.6 x | 11.7 x | 6.14 x |
| EV / Revenue | - | - | 65.6 x | 55.3 x | 31.5 x | 15.5 x | 10.5 x | 5.35 x |
| EV / EBITDA | -4.93 x | -8.4 x | -1.22 x | -7.37 x | -13.4 x | -7.42 x | -12.4 x | -18.1 x |
| EV / FCF | -5.67 x | -9.34 x | -1.22 x | -7.53 x | -17.9 x | -7.09 x | -16.2 x | 158 x |
| FCF Yield | -17.6% | -10.7% | -82.2% | -13.3% | -5.58% | -14.1% | -6.18% | 0.63% |
| Price to Book | 3.59 x | 7.9 x | 1.77 x | 6.24 x | 16.1 x | 4.83 x | 4.11 x | 5.19 x |
| Nbr of stocks (in thousands) | 43,926 | 44,205 | 50,268 | 56,348 | 59,096 | 60,973 | - | - |
| Reference price 2 | 22.96 | 29.73 | 9.980 | 29.12 | 45.97 | 35.68 | 35.68 | 35.68 |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 3.154 | 23.64 | 77.43 | 123.4 | 186 | 354.3 |
| EBITDA 1 | -145.2 | -135.9 | -168.9 | -177.5 | -182.6 | -257.8 | -157.1 | -105 |
| EBIT 1 | -146 | -136.6 | -170.1 | -179.2 | -184.4 | -273.5 | -158.7 | -11.83 |
| Operating Margin | - | - | -5,391.85% | -757.92% | -238.1% | -221.69% | -85.34% | -3.34% |
| Earnings before Tax (EBT) 1 | -140.7 | -134 | -69.61 | -181.1 | -184.1 | -274.5 | -166.7 | 3.521 |
| Net income 1 | -140.7 | -134 | -69.61 | -181.1 | -184.7 | -274.8 | -159.1 | -24.57 |
| Net margin | - | - | -2,207.1% | -766.22% | -238.52% | -222.77% | -85.55% | -6.93% |
| EPS 2 | -3.860 | -3.040 | -1.400 | -3.470 | -3.200 | -4.436 | -2.431 | 0.0217 |
| Free Cash Flow 1 | -126.1 | -122.2 | -170.1 | -173.7 | -136.2 | -270 | -120.5 | 12 |
| FCF margin | - | - | -5,391.85% | -734.87% | -175.91% | -218.88% | -64.79% | 3.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.817 | 1.498 | 9.066 | 4.284 | 8.79 | 11.47 | 19.22 | 22.5 | 24.23 | 25.97 | 29.29 | 32.41 | 35.78 | 40.22 | 39.71 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -50.99 | -52.69 | -45.1 | -39.27 | -42.1 | -52.53 | -46.6 | -43.95 | -41.26 | -139.9 | -44.35 | -48.8 | -44.09 | -39.58 | -33.98 |
| Operating Margin | -2,806.27% | -3,517.42% | -497.42% | -916.6% | -478.99% | -458.03% | -242.46% | -195.31% | -170.28% | -538.71% | -151.4% | -150.57% | -123.23% | -98.4% | -85.56% |
| Earnings before Tax (EBT) 1 | -50.86 | -52.76 | -45 | -40.86 | -42.49 | -52.18 | -46.7 | -43.8 | -41.42 | -141.1 | -43.38 | -50.4 | -42.56 | - | - |
| Net income 1 | -42.87 | -52.76 | -45 | -40.86 | -42.49 | -52.18 | -46.7 | -44.16 | -41.62 | -141.4 | -44.09 | -49.35 | -44.04 | -36.77 | -34.63 |
| Net margin | -2,359.22% | -3,522.3% | -496.37% | -953.8% | -483.42% | -454.96% | -242.98% | -196.25% | -171.75% | -544.43% | -150.5% | -152.27% | -123.08% | -91.41% | -87.21% |
| EPS 2 | -0.8500 | -1.050 | -0.8900 | -0.7900 | -0.7400 | -0.9200 | -0.8200 | -0.7600 | -0.7000 | -2.350 | -0.7038 | -0.7712 | -0.6725 | -0.5900 | -0.5500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/3/22 | 8/2/22 | 11/8/22 | 3/1/23 | 5/2/23 | 8/1/23 | 11/7/23 | 2/22/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 293 | 173 | 295 | 333 | 276 | 262 | 225 | 278 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -126 | -122 | -170 | -174 | -136 | -270 | -121 | 12 |
| ROE (net income / shareholders' equity) | -53.4% | -59.9% | -30.9% | -66.1% | -85.1% | -180% | -70.1% | -39.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 6.390 | 3.760 | 5.650 | 4.670 | 2.860 | 7.380 | 8.680 | 6.880 |
| Cash Flow per Share 2 | -3.370 | -2.760 | -2.940 | -3.330 | -2.360 | -4.070 | -1.870 | - |
| Capex 1 | 3.39 | - | 0.43 | 0.28 | 0.05 | 1.5 | 3 | - |
| Capex / Sales | - | - | 13.76% | 1.19% | 0.06% | 1.22% | 1.61% | - |
| Announcement Date | 3/2/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
35.68
USD
Average target price
57.22
USD
Spread / Average Target
+60.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.38% | 2.18B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- RYTM Stock
- Financials Rhythm Pharmaceuticals, Inc.
